Top

BMC Health Services Research

Published in:

Open Access 01-12-2015 | Research article

Medicaid prescription limits: policy trends and comparative impact on utilization

Authors: Daniel A. Lieberman, Jennifer M. Polinski, Niteesh K. Choudhry, Jerry Avorn, Michael A. Fischer

Published in: BMC Health Services Research | Issue 1/2016

Abstract

Background

Medicaid programs face growing pressure to control spending. Despite evidence of clinical harms, states continue to impose policies limiting the number of reimbursable prescriptions (caps). We examined the recent use of prescription caps by Medicaid programs and the impact of policy implementation on prescription utilization.

Methods

We identified Medicaid cap policies from 2001–2010. We classified caps as applying to all prescriptions (overall caps) or only branded prescriptions (brand caps). Using state-level, aggregate prescription data, we developed interrupted time-series analyses to evaluate the impact of implementing overall caps and brand caps in a subset of states with data available before and after cap initiation. For overall caps, we examined the use of essential medications, which were classified as preventive or as providing symptomatic benefit. For brand caps, we examined the use of all branded drugs as well as branded and generic medications among classes with available generic replacements.

Results

The number of states with caps increased from 12 in 2001 to 20 in 2010. Overall cap implementation (n = 3) led to a 0.52 % (p < 0.001) annual decrease in the proportion of essential prescriptions but no change in cost. For preventive essential medications, overall caps led to a 1.12 % (p = 0.001) annual decrease in prescriptions (246,000 prescriptions annually) and a 1.20 % (p < 0.001) decrease in spending (−$12.2 million annually), but no decrease in symptomatic essential medication use. Brand cap implementation (n = 6) led to an immediate 2.29 % (p = 0.16) decrease in branded prescriptions and 1.26 % (p = 0.025) decrease in spending. For medication classes with generic replacements, the decrease in branded prescriptions (0.74 %, p = 0.003) approximately equaled the increase in generics (0.79 %, p = 0.009), with estimated savings of $17.4 million.

Conclusions

An increasing number of states are using prescription caps, with mixed results. Overall caps decreased the use of preventive but not symptomatic essential medications, suggesting that patients assign higher priority to agents providing symptomatic benefit when faced with reimbursement limits. Among medications with generic replacements, brand caps shifted usage from branded drugs to generics, with considerable savings. Future research should analyze the patient-level impact of these policies to measure clinical outcomes associated with these changes.

Available only for authorised users

The Kaiser Family Foundation’s State Health Facts. Medicaid & CHIP. http://kff.org/state-category/medicaid-chip/ Accessed Jan 10, 2015.

Smith V, Gifford K, Ellis E, Rudowitz R, Snyder L. Moving Ahead Amid Fiscal Challenges: A Look at Medicaid Spending, Coverage and Policy Trends Results from a 50-State Medicaid Budget Survey for State Fiscal Years 2011 and 2012. Washington, DC: Kaiser Commission on Medicaid and the Uninsured; 2011.

Smith V, Gifford K, Nardone M, Rudowitz R, Snyder L. A Mid-Year State Medicaid Budget Update for FY 2012 & A Look Forward to FY 2013. Washington, DC: Kaiser Commission on Medicaid and the Uninsured; 2012.

Soumerai SB, Avorn J, Ross-Degnan D, Gortmaker S. Payment restrictions for prescription drugs under Medicaid. Effects on therapy, cost, and equity. N Engl J Med. 1987;317(9):550–6.CrossRefPubMed

Soumerai SB, Ross-Degnan D, Avorn J, McLaughlin TJ, Choodnovskiy I. Effects of Medicaid drug-payment limits on admission to hospitals and nursing homes. N Engl J Med. 1991;325(15):1072–7.CrossRefPubMed

Soumerai SB, McLaughlin TJ, Ross-Degnan D, Casteris CS, Bollini P. Effects of a limit on Medicaid drug-reimbursement benefits on the use of psychotropic agents and acute mental health services by patients with schizophrenia. N Engl J Med. 1994;331(10):650–5.CrossRefPubMed

Goldman DP, Joyce GF, Zheng Y. Prescription drug cost sharing: associations with medication and medical utilization and spending and health. JAMA. 2007;298(1):61–9.CrossRefPubMed

Austvoll-Dahlgren A, Aaserud M, Vist G, Ramsay C, Oxman AD, Sturm H, et al. Pharmaceutical policies: effects of cap and co-payment on rational drug use. Cochrane Database Syst Rev. 2008;1:CD007017.

The Kaiser Family Foundation’s State Health Facts. Medicaid Benefits: Prescription Drugs. [http://kff.org/medicaid/state-indicator/prescription-drugs/] Accessed January 10, 2015.

10.

National Pharmaceutical Council. Pharmaceutical Benefits Under State Medical Assistance Programs, 2001-2005, 2007 . Reston, VA : 2000, 2001, 2002, 2003, 2004, 2005 & 2007.

11.

Medicaid Drug Rebate Program Data. Baltimore, MD: Center for Medicare and Medicaid Services; 2001–2009.

12.

First DataBank, National Drug Data File. San Francisco, CA: Hearst Corporation; 2011.

13.

Tamblyn R, Laprise R, Hanley JA, Abrahamowicz M, Scott S, Mayo N, et al. Adverse events associated with prescription drug cost-sharing among poor and elderly persons. JAMA. 2001;285(4):421–9.CrossRefPubMed

14.

WHO Model List of Essential Medicines. 17 edition. Geneva, Switzerland: World Health Organization; 2012.

15.

De Smet BD, Fendrick AM, Stevenson JG, Bernstein SJ. Over and under-utilization of cyclooxygenase-2 selective inhibitors by primary care physicians and specialists: the tortoise and the hare revisited. J Gen Intern Med. 2006;21(7):694–7.CrossRefPubMedPubMedCentral

16.

Heidelbaugh JJ, Goldberg KL, Inadomi JM. Magnitude and economic effect of overuse of antisecretory therapy in the ambulatory care setting. Am J Manag Care. 2010;16(9):e228–234. e228-234.PubMed

17.

Patorno E, Bohn RL, Wahl PM, Avorn J, Patrick AR, Liu J, et al. Anticonvulsant medications and the risk of suicide, attempted suicide, or violent death. JAMA. 2010;303(14):1401–9.CrossRefPubMed

18.

Paul IM, Maselli JH, Hersh AL, Boushey HA, Nielson DW, Cabana MD. Antibiotic prescribing during pediatric ambulatory care visits for asthma. Pediatrics. 2011;127(6):1014–21.CrossRefPubMed

19.

Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. 32 edition. Silver Spring, MD: U.S. Food and Drug Administration; 2012.

20.

Fischer MA, Schneeweiss S, Avorn J, Solomon DH. Medicaid prior-authorization programs and the use of cyclooxygenase-2 inhibitors. N Engl J Med. 2004;351(21):2187–94.CrossRefPubMed

21.

Fischer MA, Choudhry NK, Winkelmayer WC. Impact of Medicaid prior authorization on angiotensin-receptor blockers: can policy promote rational prescribing? Health Aff (Millwood). 2007;26(3):800–7.CrossRef

22.

Stolwijk AM, Straatman H, Zielhuis GA. Studying seasonality by using sine and cosine functions in regression analysis. J Epidemiol Community Health. 1999;53(4):235–8.CrossRefPubMedPubMedCentral

23.

Polinski JM, Shrank WH, Huskamp HA, Glynn RJ, Liberman JN, Schneeweiss S. Changes in drug utilization during a gap in insurance coverage: an examination of the medicare Part D coverage gap. PLoS Med. 2011;8(8):e1001075–5.CrossRefPubMedPubMedCentral

24.

Bruen B, Ghosh A. Medicaid Prescription Drug Spending and Use. Washington, DC: Kaiser Commission on Medicaid and the Uninsured; 2004.

25.

LaRosa JC, He J, Vupputuri S. Effect of statins on risk of coronary disease: a meta-analysis of randomized controlled trials. JAMA. 1999;282(24):2340–6.CrossRefPubMed

26.

Garg R, Yusuf S. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. Collaborative Group on ACE Inhibitor Trials. JAMA. 1995;273(18):1450–6.CrossRefPubMed

27.

Rasmussen JN, Chong A, Alter DA. Relationship between adherence to evidence-based pharmacotherapy and long-term mortality after acute myocardial infarction. JAMA. 2007;297(2):177–86.CrossRefPubMed

28.

Ho PM, Rumsfeld JS, Masoudi FA, McClure DL, Plomondon ME, Steiner JF, et al. Effect of medication nonadherence on hospitalization and mortality among patients with diabetes mellitus. Arch Intern Med. 2006;166(17):1836–41.CrossRefPubMed

29.

Schiller JS, Lucas JW, Ward BW, Peregoy JA. Summary health statistics for U.S. adults: National Health Interview Survey. Vital Health Stat 10. 2010;2012(252):1–207.

30.

Newby LK, LaPointe NMA, Chen AY, Kramer JM, Hammill BG, DeLong ER, et al. Long-term adherence to evidence-based secondary prevention therapies in coronary artery disease. Circulation. 2006;113(2):203–12.CrossRefPubMed

31.

Garner JB. Problems of nonadherence in cardiology and proposals to improve outcomes. Am J Cardiol. 2010;105(10):1495–501.CrossRefPubMed

32.

Shrank WH, Choudhry NK, Liberman JN, Brennan TA. The use of generic drugs in prevention of chronic disease is far more cost-effective than thought, and may save money. Health Aff (Millwood). 2011;30(7):1351–7.CrossRef

33.

Casalino LP, Nicholson S, Gans DN, Hammons T, Morra D, Karrison T, et al. What does it cost physician practices to interact with health insurance plans? Health Aff (Millwood). 2009;28(4):w533–43.CrossRef

34.

Hsu J, Price M, Huang J, Brand R, Fung V, Hui R, et al. Unintended consequences of caps on Medicare drug benefits. N Engl J Med. 2006;354(22):2349–59.CrossRefPubMed

35.

Fischer MA, Avorn J. Economic implications of evidence-based prescribing for hypertension: can better care cost less? JAMA. 2004;291(15):1850–6.CrossRefPubMed

36.

Choudhry NK, Levin R, Avorn J. The economic consequences of non-evidence-based clopidogrel use. American Heart Journal. 2008;155(5):904–9.CrossRefPubMed

37.

Desai NR, Shrank WH, Fischer MA, Avorn J, Liberman JN, Schneeweiss S, et al. Patterns of medication initiation in newly diagnosed diabetes mellitus: quality and cost implications. Am J Med. 2012;125(3):302. e301-307-302.e301-307.CrossRefPubMedPubMedCentral

38.

Martin BC, McMillan JA. The impact of implementing a more restrictive prescription limit on Medicaid recipients. Effects on cost, therapy, and out-of-pocket expenditures. Med Care. 1996;34(7):686–701.CrossRefPubMed

39.

Greenland S, Morgenstern H. Ecological bias, confounding, and effect modification. Int J Epidemiol. 1989;18(1):269–74.CrossRefPubMed

40.

Choudhry NK, Shrank WH. Four-dollar generics--increased accessibility, impaired quality assurance. N Engl J Med. 2010;363(20):1885–7.CrossRefPubMed

41.

Sada MJ, French WJ, Carlisle DM, Chandra NC, Gore JM, Rogers WJ. Influence of payor on use of invasive cardiac procedures and patient outcome after myocardial infarction in the United States. Participants in the National Registry of Myocardial Infarction. J Am Coll Cardiol. 1998;31(7):1474–80.CrossRefPubMed

42.

The Medicaid Access Study Group. Access of Medicaid recipients to outpatient care. N Engl J Med. 1994;330(20):1426–30.CrossRef

43.

Asplin BR, Rhodes KV, Levy H, Lurie N, Crain AL, Carlin BP, et al. Insurance status and access to urgent ambulatory care follow-up appointments. JAMA. 2005;294(10):1248–54.CrossRefPubMed

44.

Smith V, Gifford K, Ellis E, Rudowitz R, Watts MO, Marks C. The Crunch Continues: Medicaid Spending, Coverage and Policy in the Midst of a Recession. Washington, DC: Kaiser Commission on Medicaid and the Uninsured; 2009.

45.

Library of Congress, Bill Summary & Status - 111th Congress (2009–2010) - H.R.3590 - CRS Summary [http://thomas.loc.gov/cgi-bin/bdquery/z?d111:H.R.3590:]. Accessed January 10, 2015.

46.

Holahan J, Headen I. Report and Briefing on Medicaid Coverage and Spending in Health Reform: National and State-By-State Results for Low-Income Adults. Washington, DC: Kaiser Commission on Medicaid and the Uninsured; 2010.

47.

Musumeci M. A Guide to the Supreme Court’s Affordable Care Act Decision. Washington, DC: Kaiser Commission on Medicaid and the Uninsured; 2012.

Title: Medicaid prescription limits: policy trends and comparative impact on utilization
Authors: Daniel A. Lieberman
Jennifer M. Polinski
Niteesh K. Choudhry
Jerry Avorn
Michael A. Fischer
Publication date: 01-12-2015
Publisher: BioMed Central
Published in: BMC Health Services Research / Issue 1/2016
Electronic ISSN: 1472-6963
DOI: https://doi.org/10.1186/s12913-016-1258-0

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Medicaid prescription limits: policy trends and comparative impact on utilization

Abstract

Background

Methods

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2016

The accuracy and completeness for receipt of colorectal cancer care using Veterans Health Administration administrative data

Issues in healthcare services in Malaysia as experienced by Japanese retirees

What do patients and the public know about clinical practice guidelines and what do they want from them? A qualitative study

Optimal use of external demands in hospitals - a Delphi study from the Netherlands

Organizational factors associated with Health Care Provider (HCP) influenza campaigns in the Veterans health care system: a qualitative study

Accessibility of ophthalmic healthcare for residents of an offshore island—an example of integrated delivery system